Revelation Biosciences Secures Nasdaq Listing Continuation

Revelation Biosciences Achieves Nasdaq Listing Continuation

Revelation Biosciences, Inc. (NASDAQ: REVB), a clinical-stage life sciences company known for its innovative approaches to immune therapies, has received vital news from the Nasdaq Hearings Panel. The panel granted the Company’s request to maintain its listing on The Nasdaq Stock Market. This decision hinges on ensuring that Revelation’s stock trades at or above $1.00 for a span of ten consecutive trading days.

Regaining Compliance with Nasdaq Standards

In conjunction with the listing approval, the Nasdaq Hearings Panel confirmed that Revelation has successfully regained compliance with the Equity Requirement of Listing Rule 5550(b)(1). This rule had previously posed issues for the Company, leading to a notice of delisting on August 14 of the past year.

Leadership's Reaction to Nasdaq's Decision

James Rolke, the Chief Executive Officer of Revelation, expressed gratitude towards the Nasdaq Hearings Panel for recognizing the Company’s strides following challenges post-SPAC merger. Rolke emphasized that since settling obligations from this merger, the focus can shift back to actualizing the development of Gemini, the Company’s leading investigational therapy. He also noted the anticipation around launching the Phase 1b clinical study targeting chronic kidney disease patients shortly.

Recent Developments in Clinical Studies

Earlier, in December, Revelation successfully exercised warrants for a total of $4 million. During the same timeframe, the Company celebrated the FDA's acceptance of its Investigational New Drug (IND) application for Gemini. The initiation of the Phase 1b clinical trial is slated for the first half of the upcoming year, marking another significant milestone for the Company. Additionally, Revelation achieved a crucial development, completing Good Manufacturing Practice (GMP) manufacture of the Gemini drug product, a critical step in the journey towards clinical trials.

Understanding Gemini: A Key Treatment Development

Gemini represents a proprietary formulation aimed at reducing inflammation by reprogramming the innate immune response to address stressors such as trauma or infection. Revelation has undertaken numerous preclinical studies that point towards the therapeutic potential of Gemini in treating various medical conditions. Earlier data from Phase 1 clinical trials indicate that Gemini effectively meets its primary safety endpoint with notable pharmacodynamic activity, including the expected modulation of biomarkers such as IL-10.

Multiple Applications for Gemini

The development of Gemini is directed towards several medical implications. It is being explored as a preventative measure against acute kidney injury (in the GEMINI-AKI program) and as a preemptive treatment to reduce the severity of post-surgical infections (in the GEMINI-PSI program). Further, the potential role of Gemini in managing chronic kidney disease is being explored under the GEMINI-CKD program, showcasing the broad applicability of this innovative therapy.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a pioneering clinical stage life sciences company committed to leveraging the potential of trained immunity for disease prevention and treatment. With its flagship formulation, Gemini, Revelation is diligently working on various programs aimed at preventing post-surgical infections, mitigating acute kidney injury risks, and treating chronic kidney disease, thereby contributing to significant advancements in medical science.

Frequently Asked Questions

What is the recent announcement regarding Revelation Biosciences?

Revelation Biosciences announced that it has received approval from the Nasdaq Hearings Panel to continue its listing, provided it meets stock price requirements.

What is Gemini, and why is it important?

Gemini is a proprietary formulation designed to help reduce inflammation and manage stress responses, with potential applications in treating various diseases, including kidney conditions.

How has Revelation's leadership responded to the Nasdaq decision?

The CEO, James Rolke, has expressed gratitude to the Nasdaq Hearings Panel, showcasing optimism about the company’s future developments.

What are the future plans for Gemini clinical studies?

The Company plans to initiate its Phase 1b study on Gemini in chronic kidney patients in the near future, following the resolution of previous obligations from the SPAC merger.

What milestones has Revelation recently achieved?

Revelation has successfully exercised warrants for $4 million and achieved FDA acceptance for the Gemini IND, marking significant progress in its clinical development.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.